Misplaced Pages

DOV-102,677: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 17:24, 14 January 2011 editEdgar181 (talk | contribs)Extended confirmed users196,325 edits added Category:Cyclopropanes using HotCat← Previous edit Latest revision as of 04:32, 16 January 2024 edit undoClueBot NG (talk | contribs)Bots, Pending changes reviewers, Rollbackers6,439,790 editsm Reverting possible vandalism by 173.64.94.7 to version by Entranced98. Report False Positive? Thanks, ClueBot NG. (4295242) (Bot)Tag: Rollback 
(56 intermediate revisions by 32 users not shown)
Line 1: Line 1:
{{short description|Chemical compound}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
⚫ | IUPAC_name = (5R)-5-(3,4-dichlorophenyl)bicyclohexane
| Watchedfields = changed
| image = DOV-102,677 structure.png
| verifiedrevid = 407870872
⚫ | CAS_number =
⚫ | IUPAC_name = (1S,5R)-1-(3,4-dichlorophenyl)-3-azabicyclohexane
⚫ | ATC_prefix =
| image = DOV-102677.svg
⚫ | ATC_suffix =
| width = 170
| PubChem =

| chemical_formula =
<!--Clinical data-->
| molecular_weight =
| bioavailability = | tradename =
⚫ | pregnancy_category =
⚫ | protein_bound =
| legal_US = Investigational New Drug
⚫ | metabolism =
⚫ | legal_status =
⚫ | elimination_half-life =
⚫ | routes_of_administration =
⚫ | excretion =

⚫ | pregnancy_category=
<!--Pharmacokinetic data-->
⚫ | legal_status =
| bioavailability =
⚫ | routes_of_administration =
⚫ | protein_bound =
⚫ | metabolism =
⚫ | elimination_half-life =
⚫ | excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
⚫ | CAS_number = 410074-75-8
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NS8NWQ6NF4
⚫ | ATC_prefix =
⚫ | ATC_suffix =
| PubChem = 11637190
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 9811932
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 488638

<!--Chemical data-->
| C=11 | H=11 | Cl=2 | N=1
| smiles = C121(CNC2)C3=CC(=C(C=C3)Cl)Cl
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = BSMNRYCSBFHEMQ-GZMMTYOYSA-N
}} }}


'''DOV 102,677''' is a ] being ] by ] as an ] and is currently in ].<ref name="Popik">{{Cite pmid|16636898}}</ref> It is a so-called ] (TUI), or ] (SNDRI).<ref name="Popik"/> '''DOV-102,677''' is a ] being ] by ] and is currently in ].<ref name="Popik">{{cite journal | vauthors = Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS | display-authors = 6 | title = Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677 | journal = Cellular and Molecular Neurobiology | volume = 26 | issue = 4–6 | pages = 857–73 | year = 2006 | pmid = 16636898 | doi = 10.1007/s10571-006-9012-5 | s2cid = 34989472 }}</ref> It is a ] (TRI), or ] (SNDRI).<ref name="Popik"/> It is the (−)-enantiomer of ], and its (+)-enantiomer is DOV-21,947 (]).

Instead of being developed for ], DOV-102,677 is being developed for the treatment of ].<ref>{{cite journal | vauthors = McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS | title = Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat | journal = Alcoholism: Clinical and Experimental Research | volume = 31 | issue = 11 | pages = 1866–71 | date = November 2007 | pmid = 17908267 | doi = 10.1111/j.1530-0277.2007.00513.x }}</ref>


⚫ ] values for the ], ] and ] are 129 nM, 103 nM, and 133 nM.<ref name="Popik"/>
Instead of being developed for ], DOV-102,677 is being developed for the treatment of ].<ref>{{Cite pmid|17908267}}</ref>


]
⚫ ] values for the ], ] and ] are 129 nM, 103 nM, and 133 nM.<ref name="Popik"/>


]
{| class="wikitable" border="1" {| class="wikitable" border="1"
|- |-
! rowspan=2 | Com ! rowspan=2 | Compound
! colspan=3 | Uptake ! colspan=3 | Uptake
! colspan=3 | Binding ! colspan=3 | Binding
Line 38: Line 65:
! DAT ! DAT
|- |-
|DOV-216,303
|216303
|14 |14
|20 |20
Line 46: Line 73:
|190 |190
|- |-
|Amitifadine
|21947
|12 |12
|23 |23
Line 54: Line 81:
|210 |210
|- |-
|DOV-102,677
|102677
|130 |130
|100 |100
Line 62: Line 89:
|220 |220
|- |-
|}{{clear left}}
|}


"DOV 102,677 (20 mg/kg IP) increased extracellular levels of DA and 5-HT in the prefrontal cortex to 320 and 280% above baseline 100 min after administration. DA levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. NE levels increased linearly to a maximum of 348% at 240 min post-dosing."<ref name="Popik"/> DOV-102,677 (20&nbsp;mg/kg IP) increased extracellular levels of dopamine and serotonin in the prefrontal cortex to 320 and 280% above baseline 100 min after administration. Dopamine levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. Norepinephrine levels increased linearly to a maximum of 348% at 240 min post-dosing.<ref name="Popik"/>
==Chemistry==

DOV scientists and their collaborators have developed an efficient, asymmetric synthesis of 102,677.<ref>Skolnick P, Basile A, Chen Z (2006) {{Cite patent|WO|2006096810}}</ref>
]
This economical and robust new route uses phenylacetonitrile and (R)-] as starting materials to synthesize 102,677 in 3 steps:
#Phenylacetonitrile is reacted with (R)-epichlorohydrin in the presence of base to give the cyclopropyl compounds.
#The nitrile group is then hydrogenated into the amino alcohol compounds.
#Cyclization is achieved with SOCl<sub>2</sub> under acidic conditions.
#The product is neutralized with base.


== References == == References ==
{{Reflist|2}} {{Reflist}}



{{Drugs used in addictive disorders}}
{{Antidepressants}}
{{Monoamine reuptake inhibitors}}
{{Anxiolytics}}
{{Stimulants}}
{{Psychostimulants}}
{{Adrenergics}}
{{Dopaminergics}}
{{Serotonergics}}


] ]
]
] ]
]




{{nervous-system-drug-stub}} {{psychoactive-stub}}

Latest revision as of 04:32, 16 January 2024

Chemical compound Pharmaceutical compound
DOV-102,677
Legal status
Legal status
Identifiers
IUPAC name
  • (1S,5R)-1-(3,4-dichlorophenyl)-3-azabicyclohexane
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H11Cl2N
Molar mass228.12 g·mol
3D model (JSmol)
SMILES
  • C121(CNC2)C3=CC(=C(C=C3)Cl)Cl
InChI
  • InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m0/s1
  • Key:BSMNRYCSBFHEMQ-GZMMTYOYSA-N
  (what is this?)  (verify)

DOV-102,677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the (−)-enantiomer of DOV-216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine).

Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism.

IC50 values for the SERT, NET and DAT are 129 nM, 103 nM, and 133 nM.

DOV stereochemistry
DOV stereochemistry
Compound Uptake Binding
5-HT NE DA SERT NET DAT
DOV-216,303 14 20 78 190 380 190
Amitifadine 12 23 96 100 260 210
DOV-102,677 130 100 130 740 1000 220

DOV-102,677 (20 mg/kg IP) increased extracellular levels of dopamine and serotonin in the prefrontal cortex to 320 and 280% above baseline 100 min after administration. Dopamine levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. Norepinephrine levels increased linearly to a maximum of 348% at 240 min post-dosing.

References

  1. ^ Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, et al. (2006). "Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677". Cellular and Molecular Neurobiology. 26 (4–6): 857–73. doi:10.1007/s10571-006-9012-5. PMID 16636898. S2CID 34989472.
  2. McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS (November 2007). "Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat". Alcoholism: Clinical and Experimental Research. 31 (11): 1866–71. doi:10.1111/j.1530-0277.2007.00513.x. PMID 17908267.
Treatment of drug dependence (N07B)
Nicotine dependence
Alcohol dependence
Opioid dependence
Benzodiazepine dependence
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins


Stub icon

This psychoactive drug-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
DOV-102,677: Difference between revisions Add topic